Literature DB >> 12466971

Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification.

Narayan Shivapurkar1, Jyotsna Reddy, Hittu Matta, Ubaradka G Sathyanarayana, C X Huang, Shinichi Toyooka, John D Minna, Preet M Chaudhary, Adi F Gazdar.   

Abstract

We have previously reported that the key apoptosis related gene caspase 8 (CASP8) is frequently silenced in small cell lung cancer (SCLC) tumors and cell lines usually, but not always, by aberrant promoter methylation. Because CASP8 is a key component of the death-inducing signaling complex (DISC) when specific death receptors (including DR4, DR5, FAS) are activated by their specific ligands (TRAIL/FASL), we examined expression of the components of the DISC complex in lung cancer cell lines. MYC family members are frequently amplified (MYC+ve) in SCLC, and MYC is a potent inducer of apoptosis. We examined 34 SCLC lines (12 of which were MYC+ve) and 22 NSCLC lines. CASP8 gene expression was frequently lost (79%) at message and protein levels in SCLC but not in non-SCLC (NSCLC). MYC amplification was present in 45% of SCLC cell lines, which had lost CASP8 expression, but not in any of the CASP8 positive lines. The frequency of CASP8 loss was significantly higher in MYC+ve SCLC compared to MYC-ve SCLC or in NSCLC. Analyses of other DISC components showed significantly higher rates of loss of expression of CASP10, DR5, FAS and FASL in SCLC compared to NSCLC. The loss of expression of proapoptotic DISC components was significantly higher in MYC+ve SCLC cell lines and these lines were completely resistant to TRAIL. Expression of CASP10 (a caspase closely related to CASP8) was frequently absent at the protein level in both SCLC and NSCLC lines. Expression of c-FLIP (proteolytically inactive homolog of CASP8) was inversely related to expression of CASP8. Our major conclusions are: (a) The death receptor pathway is differently inactivated at multiple levels in lung cancer cell lines; and (b) MYC amplification in SCLC is associated with inactivation of most components of the DISC complex, with resistance to TRAIL and with expression of c-FLIP. These findings may have considerable clinical and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466971     DOI: 10.1038/sj.onc.1205941

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.

Authors:  Terri B Hunter; Neil J Manimala; Kimberly A Luddy; Tracy Catlin; Scott J Antonia
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

2.  Bromodomain and hedgehog pathway targets in small cell lung cancer.

Authors:  Gurmeet Kaur; Russell A Reinhart; Anne Monks; David Evans; Joel Morris; Eric Polley; Beverly A Teicher
Journal:  Cancer Lett       Date:  2015-12-10       Impact factor: 8.679

Review 3.  Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?

Authors:  Adi F Gazdar; Boning Gao; John D Minna
Journal:  Lung Cancer       Date:  2010-01-15       Impact factor: 5.705

4.  X-linked ectodermal dysplasia receptor is downregulated in breast cancer via promoter methylation.

Authors:  Vasu Punj; Hittu Matta; Preet M Chaudhary
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

5.  Pharmacological inhibition of caspase-8 limits lung tumour outgrowth.

Authors:  Michela Terlizzi; Vincenzo Giuseppe Di Crescenzo; Giuseppe Perillo; Antonio Galderisi; Aldo Pinto; Rosalinda Sorrentino
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

Review 6.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

Review 7.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.

Authors:  Ahmad R Safa; Travis W Day; Ching-Huang Wu
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

8.  Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.

Authors:  Alena Vaculova; Vitaliy Kaminskyy; Elham Jalalvand; Olga Surova; Boris Zhivotovsky
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

9.  Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.

Authors:  M Stacey Ricci; Zhaoyu Jin; Michael Dews; Duonan Yu; Andrei Thomas-Tikhonenko; David T Dicker; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

10.  Perspective: Opportunities in recalcitrant, rare and neglected tumors.

Authors:  Beverly A Teicher
Journal:  Oncol Rep       Date:  2013-07-02       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.